MYCELEX by Bayer is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. First approved in 1979.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
MYCELEX (clotrimazole) is a broad-spectrum antifungal agent administered as a topical solution that inhibits pathogenic yeasts by altering cell membrane permeability. It is fungistatic at lower concentrations and may be fungicidal against Candida species at higher concentrations. The drug is indicated for oral candidiasis and other fungal infections in patients requiring topical antifungal therapy.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect defensive positioning and portfolio transition planning.
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal in vitro against Candida…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on MYCELEX at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
Working on MYCELEX offers limited growth opportunities but valuable experience in lifecycle management, generic defense, and mature product optimization. This role suits professionals seeking to develop strategic commercial acumen in a defensive, cost-focused environment rather than launch excitement.